Navigation Links
ImmunoVaccine Technologies Broadens Its Patent Protection to Japan
Date:8/5/2008

HALIFAX, Aug. 5 /PRNewswire/ - ImmunoVaccine Technologies Inc. (IVT), a vaccine development company, today announced receipt of patent approval from the Japanese Patent Office for its vaccine platform. The specific patent, Vaccines with enhanced immune response and methods for their preparation, claims broad exclusivity that an effective, long-term immune response to treat a disease can be produced using a vaccine comprising of an antigen, an adjuvant, vesicles known as liposomes, and a hydrophobic carrier.

"We have a novel technology that enhances vaccines dramatically, so receiving patent approval is important in protecting our competitive advantage," commented Dr. Marc Mansour, Vice President R&D at IVT.

Securing broad patent coverage is part of IVT's strategy to maximize the market potential of its VacciMax(R) platform in the largest pharmaceutical markets in the world; including the US, Europe, Canada, Australia and Japan. The company's VacciMax(R) technology is based on a novel approach to the use of liposomes in an oil emulsion. IVT has discovered that liposomes, stabilized in the VacciMax(R) technology, significantly enhance antibody production, creating a more rapid immune response, following a single vaccination. The responses are also long lasting, without requiring booster immunizations.

"The issuance of the patent in Japan complements the US and European patents for our vaccine platform technology," said Dr Randal Chase, President and CEO of IVT. "We are watching the growth of the Asian market, and patent coverage in Japan is an important step in contributing to the wide reach of our vaccine products."

About IVT

ImmunoVaccine Technologies Inc. is a private, clinical-stage, vaccine development company. Through its own biotech research, patented VacciMax(R) and DepoVax(TM) technologies, and collaborations with partners, IVT creates vaccines with the potential to help save and improve lives around the world.

In December 2007, IVT signed a binding MOU to acquire Pennsylvania-based Immunotope Inc. The acquisition enables IVT to create an entire pipeline of proprietary therapeutic cancer and infectious-disease specific vaccines. In January 2008, IVT licensed its technology to Pfizer Animal health, marking a pivotal step in achieving its vision of delivering breakthrough vaccines.

http://www.immunovaccine.com


'/>"/>
SOURCE ImmunoVaccine Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ImmunoVaccine Technologies Congratulates Dr. Ramila Philip as One of PAs Best 50 Women in Business
2. ImmunoVaccine Technologies Patents DepoVax(TM) Vaccine Platform
3. ImmunoVaccine Technologies appoints the Honourable Michael Kirby as Chair
4. ImmunoVaccine Technologies Inc. Nears Phase I Clinical Trials with Completion of Scientific Advisory Board
5. Neurobiological Technologies Reports Receipt of $2.1 Million Royalty Payment for Quarterly Sales of Memantine
6. MaxWell Biocorporation, LLC, and International Medical Information Technologies, Inc., Announce Partnership
7. Senesco Technologies Announces Successful Completion of First Milestone Related to Agreement with Bayer CropScience
8. [video] Edward Spink, CEO of TurboSonic Technologies, Inc. Discusses Contract With Biofuel Producer in Exclusive Interview on WallSt.nets 3-Minute Press Show
9. Local officials move toward monitoring nanotechnologies
10. VNUS Medical Technologies to Present at BMO Capital Markets 2008 Focus on Healthcare Conference
11. China Medical Technologies Adjusts Conversion Rate of Convertible Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... In a ... Hospital in Denmark detail how a patient who developed lymphedema after being treated for ... The results could change the paradigm for dealing with this debilitating, frequent side effect ...
(Date:6/23/2016)... June 23, 2016 On Wednesday, June ... 4,833.32, down 0.22%; the Dow Jones Industrial Average edged 0.27% ... at 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the ... Nektar Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. ... BIND ). Learn more about these stocks by ...
(Date:6/23/2016)... June 22, 2016  Amgen (NASDAQ: AMGN ... QB3@953 life sciences incubator to accelerate the ... shared laboratory space at QB3@953 was created to help ... obstacle for many early stage organizations - access to ... sponsorship, Amgen launched two "Amgen Golden Ticket" awards, providing ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
(Date:4/26/2016)... , April 27, 2016 ... "Global Multi-modal Biometrics Market 2016-2020"  report to their ... , The analysts forecast the global ... of 15.49% during the period 2016-2020.  ... of sectors such as the healthcare, BFSI, transportation, ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):